Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward.
William P. Horan(Neurobehavioral Systems), Philip D. Harvey(University of Miami), Michael C. Davis(Usona Institute), Florence Butlen‐Ducuing(European Medicines Agency), Dawn I. Velligan(The University of Texas at San Antonio Health Science Center), Ni A. Khin(Neurocrine Biosciences (United States)), Gary Sachs(Massachusetts General Hospital), Richard S.E. Keefe(Duke Medical Center)
PubMed
March 1, 2024
Cited by 3
Related Papers
Persistent cannabis users show neuropsychological decline from childhood to midlife
|Proceedings of the National Academy of Sciences|2012|1.5k
Self-report measures of medication adherence behavior: recommendations on optimal use
|Translational Behavioral Medicine|2015|832
Beyond hypofrontality: A quantitative meta‐analysis of functional neuroimaging studies of working memory in schizophrenia
|Human Brain Mapping|2005|622
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
|PubMed|2009|611
Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness
|Patient Preference and Adherence|2017|325